Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 92,710 | 80,871 | 78,964 | 76,247 | 253,730 |
| Marketable Securities | 860,150 | 858,066 | 814,411 | 817,463 | 751,027 |
| Receivables | 5,029 | 4,986 | 3,344 | 4,109 | 3,118 |
| Inventories | 32,034 | 30,848 | 29,605 | 27,616 | 26,429 |
| TOTAL | $1,033,109 | $1,019,464 | $968,616 | $965,600 | $1,074,189 |
| Non-Current Assets | |||||
| PPE Net | 10,675 | 10,579 | 11,067 | 11,675 | 11,819 |
| Investments And Advances | 304,341 | 400,467 | 531,253 | 638,321 | 655,889 |
| Other Non-Current Assets | 37,580 | 40,727 | 44,582 | 47,603 | 49,897 |
| TOTAL | $352,596 | $451,773 | $586,902 | $697,599 | $717,605 |
| Total Assets | $1,385,705 | $1,471,237 | $1,555,518 | $1,663,199 | $1,791,794 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 19,553 | 17,532 | 13,726 | 16,643 | 17,143 |
| Accrued Expenses | 37,217 | 35,289 | 20,761 | 46,861 | 33,307 |
| TOTAL | $74,757 | $70,410 | $52,366 | $81,156 | $119,451 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 26,618 | 31,272 | 36,624 | 41,087 | 45,671 |
| TOTAL | $26,618 | $31,272 | $36,624 | $41,087 | $45,671 |
| Total Liabilities | $101,375 | $101,682 | $88,990 | $122,243 | $165,122 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 58,314 | 58,102 | 57,915 | 57,296 | 57,030 |
| Common Shares | 74 | 74 | 74 | 73 | 73 |
| Retained earnings | -453,666 | -350,233 | -238,213 | -148,924 | -52,401 |
| Other shareholders' equity | 1,565 | 169 | -121 | -2,004 | 2,934 |
| TOTAL | $1,284,330 | $1,369,555 | $1,466,528 | $1,540,956 | $1,626,672 |
| Total Liabilities And Equity | $1,385,705 | $1,471,237 | $1,555,518 | $1,663,199 | $1,791,794 |